BioNTech (BNTX) vs Neurocrine Biosciences (NBIX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Neurocrine Biosciences (NBIX) has outperformed BioNTech (BNTX) over the past year, gaining 4.7% versus a loss of 10.2%. Over five years, NBIX leads with a +37.2% price change compared with -61.5% for BNTX. BioNTech is the larger company by market cap ($23.93 billion vs $14.58 billion), about 1.6 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BNTX | NBIX |
|---|---|---|
| Share price | $95.25 | $143.47 |
| Market cap | $23.93B | $14.58B |
| 1-day change | -0.50% | -1.40% |
| YTD return | +0.05% | +1.16% |
| 1-year return | -10.19% | +4.72% |
| 5-year return | -61.54% | +37.24% |
| P/E ratio (TTM) | — | 21.32 |
| Forward P/E | — | 12.08 |
| EPS (TTM) | $-7.79 | $6.73 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $2.86B |
| Revenue growth (YoY) | — | +21.45% |
| Net income (latest FY) | — | $478.60M |
| Gross margin | — | 98.18% |
| Operating margin | — | 21.64% |
| Net margin | — | 16.73% |
| 52-week high | $124.00 | $186.12 |
| 52-week low | $79.52 | $122.14 |
| Distance from 52-week high | -23.19% | -22.92% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +21.56% | +44.48% |
| Average volume | 1.16M | 1.30M |
| Shares outstanding | 251.20M | 101.65M |
| Employees | 7,807 | 2,500 |
| Sector | Health Care | Healthcare |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Drug Manufacturers - Specialty & Generic |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- NBIX has outperformed BNTX by 14.9 percentage points over the past year.
- The two companies sit in different sectors: BioNTech in Health Care and Neurocrine Biosciences in Healthcare.
About BioNTech
BNTX stock →BioNTech SE, together with its subsidiaries, engages in the development and commercialization of immunotherapies in Germany. The company offers BNT162, an mRNA vaccine for the treatment of SARS-CoV-2 virus.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 7,807 employees
About Neurocrine Biosciences
NBIX stock →Neurocrine Biosciences, Inc. discovers, develops, and commercialize pharmaceuticals for neurological, psychiatric, endocrine, and immunological disorders in the United States and internationally.
Healthcare · Drug Manufacturers - Specialty & Generic · 2,500 employees
BNTX vs NBIX FAQ
Which is bigger, BioNTech or Neurocrine Biosciences?
BioNTech (BNTX) is larger, with a market capitalization of $23.93B compared with $14.58B for Neurocrine Biosciences (NBIX).
Which stock has performed better over the past year, BNTX or NBIX?
NBIX returned +4.72% over the past 12 months, compared with -10.19% for BNTX (price return, excluding dividends). Past performance does not predict future results.
Are BioNTech and Neurocrine Biosciences in the same industry?
No. BioNTech is in the Health Care sector, while Neurocrine Biosciences is in Healthcare.